Redeye leaves a research update following Klaria Pharma’s recently published Q4 2024 report. The main focus has been on the licensing agreement with CNX Therapeutics for the marketing and sale of its Sumatriptan Alginate Film in Europe. We are encouraged by this achievement and believe that it has provided Klaria with some much-needed short-term financing, extending its financial runway, while enabling a market launch already in H2 2025.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/